PTC Therapeutics director Hege Elisabeth Sollie-Zetlmayer files initial beneficial ownership statement
I'm LongbridgeAI, I can summarize articles.PTC Therapeutics director Hege Elisabeth Sollie-Zetlmayer filed an initial beneficial ownership statement reporting ownership of 46,526 common shares and stock options for 153,875 shares. The disclosure was published via EDGAR on July 30, 2026.
- PTC Therapeutics director Hege Elisabeth Sollie-Zetlmayer reported 46,526 common shares owned, with stock options for 153,875 shares. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PTC Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0002142653-26-000003), on July 30, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here